Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab + XELOX in elderly metastatic colorectal cancer
NCT00531115Phase 2Terminated
- Sponsor
- Spanish Cooperative Group for Digestive Tumour Therapy
- Start
- Nov 2007
- Primary completion
- Apr 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of KL-140 in metastatic colorectal cancer (mCRC), sponsored by Spanish Cooperative Group for Digestive Tumour Therapy. Primary endpoint: Objective Response Rate at 12 weeks. Started Nov 2007; status: terminated.
02
Drugs
KL-140
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00531115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00531115.